Systemic therapy for advanced hepatocellular carcinoma has expanded at an
unprecedented pace over the past 5 years. After tyrosine kinase inhibitors dominated the …

Immunotherapy has revolutionized the treatment paradigm of non-small cell lung cancer and
improved patients' prognosis. Immune checkpoint inhibitors have quickly become standard …

Background Previous studies have shown that functional systemic immunity is required for
the efficacy of PD-1/PD-L1 blockade immunotherapies in cancer. Hence, systemic …

Immunotherapies based on immune checkpoint blockade have shown remarkable clinical
outcomes and durable responses in patients with many tumor types. Nevertheless, these …

Simple Summary Cancer patients are considered a high-risk group for infectious diseases
including COVID-19. The protective effects of vaccination are unclear in oncologic patients …

Immunotherapy has emerged as a promising new treatment modality for head and neck
cancer, offering the potential for targeted and effective cancer management. Squamous cell …

Introduction Hyperprogressive disease (HPD) is a paradoxically rapid disease progression
during or shortly after antitumor treatment, especially immune checkpoint inhibitors (ICIs) …

Aims: To analyze the correlation between the neutrophil-to-lymphocyte ratio (NLR) and
prognosis of advanced gastric cancer (AGC) patients treated by PD-1 antibody-based …

Immunotherapy is now a mainstay in cancer treatments. Programmed cell death 1 (PD-
1)/programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitor (ICI) therapies have …

Background Hyper progressive disease (HPD) describes the phenomenon that patients
can't benefit from immunotherapy but cause rapid tumor progression. HPD is a particular …